H. Lundbeck A/S

HLUN B

DK0061804770

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâs disease, Bipolar disorder, depression, epilepsy, Huntingtonâs disease, Parkinsonâs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâs disease, Azilect for the treatment of Parkinsonâs disease, Xenazine for the treatment of Huntingtonâs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

H LUNDBECK : Q1 beat adds momentum to the recent share price rally

May 15, 2024 at 09:50 pm IST

More Strategies

Ratings for H. Lundbeck A/S

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

38.86 DKK

Average target price

39.96 DKK

Spread / Average Target

+2.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
H. LUNDBECK A/S	+18.62%	538.27Cr
CARDINAL HEALTH, INC.	-2.46%	2.39TCr
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+14.23%	870.36Cr
SINOPHARM GROUP CO. LTD.	+1.47%	829.3Cr
HUADONG MEDICINE CO., LTD	-32.92%	669.77Cr
GALENICA AG	+1.10%	407.87Cr
EBOS GROUP LIMITED	-9.24%	379.19Cr
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-10.20%	329.84Cr
MEDIPAL HOLDINGS CORPORATION	+7.11%	318.76Cr
CHINA NATIONAL MEDICINES CORPORATION LTD.	+7.58%	319.68Cr

Pharmaceuticals Wholesale

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 28/06/2024 pm IST			5-day change	1st Jan Change
38.86 ^DKK	+1.99%		+0.41%	+18.62%

26/06	Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application	MT
25/06	US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment	MT

Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application	26/06	MT
US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment	25/06	MT
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder	25/06	CI
H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial	19/06	CI
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia	03/06	CI
H LUNDBECK : Q1 beat adds momentum to the recent share price rally	15/05
Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024	15/05
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024	15/05	CI
H LUNDBECK : Lundbeck is well-poised to sail through the transition period	13/05
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	13/05	CI
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	09/04	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	09/04	CI
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	27/03	MT
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	27/03	CI
H. Lundbeck A/S Announces Management Appointments	20/03	CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	20/03	CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call	20/03
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	15/03	MT
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	15/03	CI
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	23/02	CI
H. Lundbeck A/S Announces Changes to Executive Management	23/02	CI
Nordic Shares Dropped Tuesday; Lundin Gold Posted Biggest Loss	13/02	DJ
Transcript : H. Lundbeck A/S, 2023 Earnings Call, Feb 07, 2024	07/02
Transcript : H. Lundbeck A/S - Special Call	31/01